The Pathway of Let-7a-1/2-3p and HMGB1 Mediated Dexmedetomidine Inhibiting Microglia Activation in Spinal Cord Ischemia-Reperfusion Injury Mice
Microglial cell activation after spinal cord ischemia-reperfusion injury (SCIRI) commonly causes the secondary nerve motion function injury. This study aims to study the mechanism by which the drug dexmedetomidine (DEX) inhibits microglial cell activation and improves motion function of SCIRI mice. Mice SCIRI model was established, and microglia from spinal cord were isolated and cultured for subsequent molecule analysis of let-7a-1-3p, let-7a-2-3p, HMGB1, TNF-α, and IL-6. DEX was given by intraperitoneal injection. Mice motion function was evaluated by Basso mouse score. In vitro microglial cells were subjected to oxygen and glucose deprivation/reoxygenation (OGD/R) to imitate ischemia-reperfusion injury stimulation. DEX injection improves the mouse motion function in SCIRI model and upregulates let-7a-1/2-3p expression in the isolated activated microglia from SCIRI mice. In OGD/R-stimulated microglia, DEX treatment also caused the inactivation of cells, the upregulation of let-7a-1/2-3p expression, and the downregulation of HMGB1 expression. While the co-silencing of let-7a-1/2-3p in microglia in addition to DEX treatment restored the activation of microglia. HMGB1 is a targeted gene for let-7a-1/2-3p and negatively regulated by them. HMGB1 knockdown abrogates the pro-activation impact on microglial cell by let-7a-1/2-3p silencing. DEX inhibits the activation of microglial cell in the spinal cord of SCIRI mice, mediated by the let-7a-1/2-3p/HMGB1 pathway.
KeywordsLet-7a-1/2-3p Dexmedetomidine Microglial cell Spinal cord ischemia-reperfusion injury
Compliance with ethical standards
All protocols involved animals have been approved by the animal ethics committee of Renmin Hospital of Wuhan University.
- Bell MT, Agoston VA, Freeman KA, Puskas F, Herson PS, Mares J, Fullerton DA, Reece TB (2014) Interruption of spinal cord microglial signaling by alpha-2 agonist dexmedetomidine in a murine model of delayed paraplegia. J Vasc Surg 59:1090–1097. https://doi.org/10.1016/j.jvs.2013.04.050 CrossRefGoogle Scholar
- Bell MT, Puskas F, Agoston VA, Cleveland JC, Freeman KA, Gamboni F, Herson PS, Meng X, Smith PD, Weyant MJ, Fullerton DA, Reece TB (2013) Toll-like receptor 4-dependent microglial activation mediates spinal cord ischemia-reperfusion injury. Circulation 128:S152–S156. https://doi.org/10.1161/CIRCULATIONAHA.112.000024 CrossRefGoogle Scholar
- Liu K, Yan L, Jiang X, Yu Y, Liu H, Gu T, Shi E (2017) Acquired inhibition of microRNA-124 protects against spinal cord ischemia-reperfusion injury partially through a mitophagy-dependent pathway. J Thorac Cardiovasc Surg 154:1498–1508. https://doi.org/10.1016/j.jtcvs.2017.05.046 CrossRefGoogle Scholar
- Paudel YN, Shaikh MF, Chakraborti A, Kumari Y, Aledo-Serrano Á, Aleksovska K, Alvim MKM, Othman I (2018) HMGB1: a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci 12:628. https://doi.org/10.3389/fnins.2018.00628 CrossRefGoogle Scholar
- Rong H, Zhao Z, Feng J, Lei Y, Wu H, Sun R, Zhang Z, Hou B, Zhang W, Sun YE, Gu X, Ma Z, Liu Y (2017) The effects of dexmedetomidine pretreatment on the pro- and anti-inflammation systems after spinal cord injury in rats. Brain Behav Immun 64:195–207. https://doi.org/10.1016/j.bbi.2017.03.006 CrossRefGoogle Scholar
- Smith PD, Bell MT, Puskas F, Meng X, Cleveland JC Jr, Weyant MJ, Fullerton DA, Reece TB (2013) Preservation of motor function after spinal cord ischemia and reperfusion injury through microglial inhibition. Ann Thorac Surg 95:1647–1653. https://doi.org/10.1016/j.athoracsur.2012.11.075 CrossRefGoogle Scholar